Volumen: 17 # Number : 2
Publication Date : Mayo - Agosto Year: 2013
LABORATORIO EN HEMATOLOGIA |
Authors: Lev P.R., Heller P.G.
Abstract: The JAK2V617 mutation is the most frequent molecular
abnormality underlying the pathogenesis of chronic myeloproliferative neoplasmas. More than 95% of patients with polycythemia vera and around half of those with essential thrombocythemia and primary myelofibrosis carry this mutation. It is useful to distinguish clonal from reactive conditions
and is one of the diagnostic criteria included in the WHO classification. It may be detected, albeit
with low frequency, in other myeloid neoplasms. Although a moderate increase in the thrombotic risk has been described for JAK2V617F-positive essential thrombocythemia patients, its presence does not represent by itself a parameter to guide treatment recommendations. Patients with high JAK2V617F allelic burden have increased risk of thrombosis and myelofibrotic transformation. However, the role of allele burden measurement in the clinical management and treatment monitoring
of patients with myeloproliferative neoplasms remains to be determined.
Key words: JAK2V617F, allele burden, myeloproliferative
neoplasms
Pages : 176-178
|
